In summary, the CD6-ADC selectively kills proliferating pathogenic T cells and is highly effective in treating 2 preclinical models of autoimmune uveitis as well as a humanized model of GVHD even when given at a low dose. Here, CD6 is linked to autoimmune uveitis.